Regeneron Reported Third Quarter Financials

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2018.  “Regeneron continues to grow and diversify our business, while continuing to deliver very strong financial results.  In addition to EYLEA reaching over $1 billion in quarterly U.S. net sales, we also made significant progress with Dupixent, a key driver of future growth, and launched Libtayo, our first immuno-oncology therapy,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  “Dupixent is now approved in the U.S. for both atopic dermatitis and asthma and under regulatory review for the treatment of adolescents with atopic dermatitis – with another submission planned in chronic rhinosinusitis with nasal polyps.  We also recently reported positive Phase 3 results for EYLEA in diabetic retinopathy, and expect an FDA action on our supplemental application for this indication in the first half of 2019.”

Regeneron has twenty product candidates in clinical development, which consist of EYLEA and fully human antibodies generated using the Company’s VelocImmune® technology. Net product sales were $1.025 billion in the third quarter of 2018, compared to $957 million in the third quarter of 2017.  EYLEA net product sales in the United States were $1.022 billion in the third quarter of 2018, compared to $953 million in the third quarter of 2017. 

1 Comment

Leave a Comment